drughunter.com
< 1 minute read
Sep. 6, 2024

Patent Highlight: Highly Selective TREX1 Inhibitors from Constellation Pharmaceuticals

Author:  
Reviewer:  
Editor:  
Loading...

twitterlinkedinemail

Other articles you may be interested in

Patent Highlights from January 2024: KRAS G12V, MAGL, and WRN Inhibitors, Nrf2 Degraders, and More

From WRN helicase to KRAS G12V, there were numerous hot targets of interest with patent applications published in January 2024. Here, we curated a searchable table comprising key information for more than 200 patents from January 2024 of potential interest to drug hunters, along with highlights from some of our favorites, including several degraders and molecules targeting Nrf2, KRAS G12V, MAGL, WRN, among others.

May 2024 Patent Highlights: STING Antagonists, WIZ Degraders, Macrocyclic Amine-Based OX2R Modulators, and More

To help you quickly scan the patent literature, we’ve distilled down thousands of new documents into a searchable table of over 200 selected patents focused on key areas in drug discovery, all published in May 2024. This resource is enriched with detailed highlights on selected molecules targeting high-interest areas such as STING antagonists, WIZ degraders, RNA degraders, and macrocyclic amine-based OX2R modulators.

Patent Highlights: Synthetic Lethal MTA-Cooperative PRMT5 Inhibitors, TYK2 Degraders, Mutant p53 Reactivators, and More

February 2024 saw numerous notable patent disclosures aimed at a variety of therapeutic targets across different disease areas. The Drug Hunter team has compiled a searchable table that includes more than 200 patents of relevance to the drug discovery industry. Accompanying the table are detailed notes, as well as standout features from some of our top picks, including MTA-cooperative PRMT5 inhibitors, heterobifunctional TYK2 degraders, strategies for engaging and reactivating mutant p53, and more.

July 2024 Annotated Searchable Patent Table

To streamline your review of the patent literature, we've distilled thousands of new documents into a searchable table featuring over 200 selected patents focused on key areas in drug discovery, all published in July 2024. Each patent includes commentary for easier navigation and understanding.

Patent Highlight: How Might Puhe BioPharma’s WRN Helicase Inhibitors Differentiate from Novartis’?

This article highlights a patent application from Puhe BioPharma that discloses the biological activity of compounds that act as WRN helicase inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.